C2N Diagnostics LLC, a St. Louis-based biotechnology firm that developed blood-based tests for Alzheimer's and other neurological diseases, has received a grant from The Michael J. Fox Foundation for ...

Many of our scientists are focussed on developing treatments that can slow down or stop the diseases that cause dementia. This work is vital, as currently there are no drugs available on the NHS that ...

The firm will use its blood-based tests to explore connections between Alzheimer's disease and neuronal α-synuclein conditions including Parkinson's disease.

Researchers from Newcastle University analyzed walking patterns of hundreds of people using a tool called 'electronic ...

Researchers at Lund University in Sweden have made a major breakthrough in diagnosing Lewy body disease, a leading cause of ...

Alzheimer's disease is the most common type of dementia. Here, we break down what to know about this disease, including: What ...

Dementia with Lewy bodies (DLB) is the most common neurodegenerative dementia after Alzheimer’s Disease, yet is usually ...

A new study from Karolinska Institutet and Mayo Clinic has revealed important insights into brain degeneration in dementia ...

A new study from Karolinska Institutet and Mayo Clinic has revealed important insights into brain degeneration in dementia ...

Continue to advance preclinical and research pipeline, including key programs selectively combined with Alector Brain Carrier, enhancing the company's commitment to developing genetically-validated th ...

ProMIS Neurosciences Inc. (Nasdaq: PMN) (ProMIS), a clinical-stage biotechnology company focused on the generation and ...

Continue to advance preclinical and research pipeline, including key programs selectively combined with Alector Brain Carrier ...